BDNF and Huntington disease: In accordance, we found that transcription of Stmn2 and Syn1, but not Bdnf, was quite vulnerable to altered REST activity (i.e. up‐regulation by mHtt and downregulation by ASOs/siRNA), suggesting that Stmn2 and Syn1 may have advantage over Bdnf as potential HD biomarkers.